Cargando…

Crystal structures of main protease (M(pro)) mutants of SARS-CoV-2 variants bound to PF-07304814

There is an urgent need to develop effective antiviral drugs to prevent the viral infection caused by constantly circulating SARS-CoV-2 as well as its variants. The main protease (M(pro)) of SARS-CoV-2 is a salient enzyme that plays a vital role in viral replication and serves as a fascinating thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Haihai, Zou, Xiaofang, Zeng, Pei, Zeng, Xiangyi, Zhou, Xuelan, Wang, Jie, Zhang, Jin, Li, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397169/ https://www.ncbi.nlm.nih.gov/pubmed/37532968 http://dx.doi.org/10.1186/s43556-023-00134-2

Ejemplares similares

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814
por: Li, Jian, et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor: Crystal structures of M (pro) mutants bound to YH-53
por: Luo, Jiqing, et al.
Publicado: (2023)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor
por: Hu, Xiaohui, et al.
Publicado: (2022)

Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection
por: Chen, Wujun, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
por: Robinson, Philip, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses
por: Zvornicanin, Sarah N., et al.
Publicado: (2023)

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
por: Ullrich, Sven, et al.
Publicado: (2022)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro)
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2020)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode
por: Li, Jian, et al.
Publicado: (2021)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system
por: Costacurta, Francesco, et al.
Publicado: (2023)

QM/QM studies for Michael reaction in coronavirus main protease (3CL(Pro))
por: Taranto, Alex G., et al.
Publicado: (2008)

Crystal Structure of Human Coronavirus NL63 Main Protease in Complex With an Inhibitor
por: Yang, Kailin, et al.
Publicado: (2015)

Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum
por: Sharma, Aabha I., et al.
Publicado: (2020)

Structure of SARS-CoV-2 main protease in the apo state
por: Zhou, Xuelan, et al.
Publicado: (2020)

Structural analysis of the coronavirus main protease for the design of pan-variant inhibitors
por: Rungruangmaitree, Runchana, et al.
Publicado: (2023)

Abnormal expression and processing of keratins in pupoid fetus (pf/pf) and repeated epilation (Er/Er) mutant mice
Publicado: (1987)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Expression, purification, and biophysical characterization of recombinant MERS-CoV main (M(pro)) protease
por: Almutairi, Ghada Obeid, et al.
Publicado: (2022)

The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M(pro))
por: Ebrahim, Ali, et al.
Publicado: (2021)

Review on development of potential inhibitors of SARS-CoV-2 main protease (M(Pro))
por: Katre, Soumya Gulab, et al.
Publicado: (2022)

The Effect of Point Mutations on Structure and Dynamics of SARS-CoV-2 Main Protease Mutants
por: Diessner, Elizabeth M., et al.
Publicado: (2021)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus
por: Zhang, Yuting, et al.
Publicado: (2022)

Crystal Structure of Inhibitor-Bound GII.4 Sydney 2012 Norovirus 3C-Like Protease
por: Eruera, Alice-Roza, et al.
Publicado: (2023)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Development of Broad‐Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CL(pro)
por: Bacha, Usman, et al.
Publicado: (2008)

In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2
por: Garg, Saksham, et al.
Publicado: (2020)

Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro))
por: Sayed, Ahmed M., et al.
Publicado: (2020)

In silico approach for identification of natural compounds as potential COVID 19 main protease (M(pro)) inhibitors
por: Chaturvedi, Monika, et al.
Publicado: (2021)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rluld0aicroa8gfrf7tqflc22m